triple glp-1/gip/glucagon receptor agonist Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data The TRIUMPH-1 Phase 3 results
Description
Tirzepatide: A Dual-Action Star SURMOUNT-1 Trial People on tirzepatide lost up to 20.9% of their body weight after 72 weeks
conceived the idea for the study
B.KramerM
[DOI] [PMC free article] [PubMed] [Google Scholar] 666.Beiroa D., Imbernon M., Gallego R., Senra A., Herranz D., Villarroya F
DPP-4 inhibitors carry a small risk of joint pain and rare reports of severe infections
